First-line targeted therapy shows antitumor activity in patients with advanced lung cancer
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), providing a safe and effective oral targeted treatment alternative to ...
12 hours ago
0
2









